Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Vbi Vaccines Inc CS (VBIV)
Vbi Vaccines Inc CS (VBIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,956
  • Shares Outstanding, K 22,872
  • Annual Sales, $ 1,080 K
  • Annual Income, $ -113,300 K
  • 60-Month Beta 1.81
  • Price/Sales 14.00
  • Price/Cash Flow N/A
  • Price/Book 1.72
Trade VBIV with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.70
  • Most Recent Earnings -2.17 on 08/14/23
  • Next Earnings Date 11/09/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.150 on 12/12/12
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 686.47% ( +42.59%)
  • Historical Volatility 78.13%
  • IV Percentile 89%
  • IV Rank 48.04%
  • IV High 1,414.67% on 02/16/23
  • IV Low 13.26% on 10/03/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 14,833
  • Open Int (30-Day) 14,803

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -2.70
  • Growth Rate Est. (year over year) +94.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5932 +5.53%
on 09/25/23
1.3080 -52.14%
on 09/07/23
-0.6040 (-49.11%)
since 08/25/23
3-Month
0.5932 +5.53%
on 09/25/23
3.4700 -81.96%
on 06/30/23
-1.3840 (-68.86%)
since 06/26/23
52-Week
0.5932 +5.53%
on 09/25/23
23.7000 -97.36%
on 09/28/22
-20.8210 (-97.08%)
since 09/26/22

Most Recent Stories

More News
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.6260 (+2.59%)
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VBIV : 0.6260 (+2.59%)
Brii Biosciences Provides Latest Clinical Development and Corporate Updates

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri® in Greater China and Asia Pacific markets New data from...

VIR : 9.25 (+0.43%)
VBIV : 0.6260 (+2.59%)
ANTX : 15.22 (+11.26%)
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio", "we", or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...

VIR : 9.25 (+0.43%)
VBIV : 0.6260 (+2.59%)
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABSI : 1.2800 (-5.19%)
VBIV : 0.6260 (+2.59%)
VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VBIV : 0.6260 (+2.59%)
MIRM : 30.38 (-1.87%)
VBI Vaccines Appoints Vaughn Himes to Board of Directors

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Vaughn B. Himes, Ph.D., Chief...

VBIV : 0.6260 (+2.59%)
VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

CRSP : 46.11 (+0.55%)
VBIV : 0.6260 (+2.59%)
CERT : 13.90 (-1.49%)
EQRX : 2.21 (unch)
VBI Vaccines Announces Increased Focus on Hepatitis B, Organizational Changes, and Reverse Stock Split

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced plans to focus the Company’s efforts...

VBIV : 0.6260 (+2.59%)
Calling All Quality Control: Get Rid of These 3 Biotech Stocks ASAP!

High-interest rates are expected to impact the growth of the biotech industry. Therefore, fundamentally weak biotech stocks Bionano Genomics (BNGO), VBI Vaccines (VBIV), and 180 Life Sciences (ATNF) might...

ATNF : 0.6000 (+7.14%)
BNGO : 2.84 (-4.70%)
VBIV : 0.6260 (+2.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

VBI Vaccines Inc. is a biopharmaceutical company developing novel technologies to expand vaccine protection. The company's eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines which closely mimic the target virus. Its lead eVLP asset is a prophylactic cytomegalovirus...

See More

Key Turning Points

3rd Resistance Point 0.7107
2nd Resistance Point 0.6853
1st Resistance Point 0.6557
Last Price 0.6260
1st Support Level 0.6007
2nd Support Level 0.5753
3rd Support Level 0.5457

See More

52-Week High 23.7000
Fibonacci 61.8% 14.8732
Fibonacci 50% 12.1466
Fibonacci 38.2% 9.4200
Last Price 0.6260
52-Week Low 0.5932

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar